Sanofi, a French pharmaceutical company, will assist in the production of Pfizer vaccine, which plans to provide 100 million doses to the European Union this year

Source Title: Sanofi, a French pharmaceutical company, will assist in the production of Pfizer vaccine. This year, it plans to provide 100 million doses to the European Union

China News Agency, Paris, January 27 (reporter Li Yang) – Sanofi, a French pharmaceutical company, confirmed on the 27th that it will assist in the production of the new crown vaccine jointly developed by Pfizer of the United States and biontech of Germany, and plans to provide 100 million doses to the European Union this year. Sanofi officially confirmed on the 27th that it has reached an agreement with two German companies to assist in the production of Pfizer vaccine. Sanofi will use its own production line and related technology to assist in the production of Pfizer vaccine. The total dose of this year’s production is preliminarily estimated to be 125 million doses. The first batch of vaccines will be delivered this summer. Sanofi CEO Hudson said the company plans to provide 100 million doses of Pfizer vaccine to the European Union this year to meet the huge demand for new vaccines in EU countries. Pfizer said this month that it would reduce the number of vaccines provided to EU countries, causing dissatisfaction from the EU. France also urged Pfizer to deliver the vaccines on time. According to French BFM television and other media, Sanofi’s assistance in the production of Pfizer vaccine at this stage will mainly focus on filling drugs and packaging. Negotiations on the production of vaccine active ingredients are still in progress. Sanofi needs to obtain the necessary logistics support and technology transfer. Sanofi said the company’s own test vaccine is still in development and may not be available until the end of this year. The test vaccine did not respond adequately to the elderly and had to be delayed. Hudson said Sanofi is now discussing ways to help fight the epidemic because of the delay in the launch of Sanofi’s vaccine. To get back to normal life, as many people as possible must be vaccinated, said bojilo, President of Sanofi France. Therefore, concerted efforts are needed in vaccine production, and Sanofi has the production capacity and expertise. Vaccination in France is still facing a shortage of vaccine supply. France will only receive 4.6 million doses of the AstraZeneca vaccine by the end of March, instead of about 16 million doses originally planned, according to the Ministry of health. This means that the progress of vaccination in France will be affected in the future. (end)

China News Agency, Paris, January 27 (reporter Li Yang) – Sanofi, a French pharmaceutical company, confirmed on the 27th that it will assist in the production of the new crown vaccine jointly developed by Pfizer of the United States and biontech of Germany, and plans to provide 100 million doses to the European Union this year.

Sanofi officially confirmed on the 27th that it has reached an agreement with two German companies to assist in the production of Pfizer vaccine. Sanofi will use its own production line and related technology to assist in the production of Pfizer vaccine. The total dose of this year’s production is preliminarily estimated to be 125 million doses. The first batch of vaccines will be delivered this summer.

Sanofi CEO Hudson said the company plans to provide 100 million doses of Pfizer vaccine to the European Union this year to meet the huge demand for new vaccines in EU countries. Pfizer said this month that it would reduce the number of vaccines provided to EU countries, causing dissatisfaction from the EU. France also urged Pfizer to deliver the vaccines on time.

According to French BFM television and other media, Sanofi’s assistance in the production of Pfizer vaccine at this stage will mainly focus on filling drugs and packaging. Negotiations on the production of vaccine active ingredients are still in progress. Sanofi needs to obtain the necessary logistics support and technology transfer.

Sanofi said the company’s own test vaccine is still in development and may not be available until the end of this year. The test vaccine did not respond adequately to the elderly and had to be delayed. Hudson said Sanofi is now discussing ways to help fight the epidemic because of the delay in the launch of Sanofi’s vaccine.

To get back to normal life, as many people as possible must be vaccinated, said bojilo, President of Sanofi France. Therefore, concerted efforts are needed in vaccine production, and Sanofi has the production capacity and expertise.

Vaccination in France is still facing a shortage of vaccine supply. France will only receive 4.6 million doses of the AstraZeneca vaccine by the end of March, instead of about 16 million doses originally planned, according to the Ministry of health. This means that the progress of vaccination in France will be affected in the future. (end)

留下评论

您的电子邮箱地址不会被公开。 必填项已用*标注